The 12th Invest in ME Research Conference June, 2017, Part 2
MEMum presents the second article in a series of three about the recent 12th Invest In ME International Conference (IIMEC12) in London.
Discuss the article on the Forums.

Prof Jonathon Edwards to be IiME Rituximab trial advisor

Discussion in 'General ME/CFS News' started by Sasha, Jul 14, 2013.

  1. Sasha

    Sasha Fine, thank you

    Messages:
    12,789
    Likes:
    34,217
    UK
    Jo Best, Bob, Esther12 and 5 others like this.
  2. Purple

    Purple Bundle of purpliness

    Messages:
    460
    Likes:
    749
    EXCELLENT NEWS!
    (yes, I did mean to shout this...)
     
    SOC, Dolphin, sproggle and 1 other person like this.
  3. user9876

    user9876 Senior Member

    Messages:
    2,584
    Likes:
    18,183
    sproggle, SOC, Esther12 and 2 others like this.
  4. Esther12

    Esther12 Senior Member

    Messages:
    8,449
    Likes:
    28,523
    Good news.

    Hopefully he might be able to advance work on finding a way of identifying those patients most likely to benefit. Linking the rituximab CFS work to others working in a similar area but outside of CFS seems like a really positive move.
     
    Sasha and Valentijn like this.
  5. Gemini

    Gemini Senior Member

    Messages:
    654
    Likes:
    1,177
    Esther,

    You're absolutely right!

    In RA they can identify non-responders to rituximab using an interferon [gene expression] signature:

    "The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients, " Arthritis Res Ther, April 2012

    http://www.ncbi.nlm.nih.gov/pubmed/22540992

    Let's hope the Professor is familiar with this groundbreaking work in another disease & can apply it to ME/CFS.
     
    Sasha and Valentijn like this.

See more popular forum discussions.

Share This Page